Overview

Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the basiliximab for prevention of graft-versus-host disease in unrelated allo-genetic hematopoietic stem cell transplantation for thalassemia major. The objective was to evaluate the effect and safety of basiliximab for acute graft-versus-host disease.

Phase:

Phase 4

Details

Lead Sponsor:

Affiliated hospital of guangxi medical university,china

Collaborators:

Kunming general Hospital of Chengdu Military Region
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Union hospital of Fujian Medical University
Zhongshan Hospital Xiamen University

Treatments:

Antibodies, Monoclonal
Basiliximab
Cyclosporine
Cyclosporins
Methotrexate
Mycophenolate mofetil
Mycophenolic Acid